0
0
March 6, 2026
BALTIMORE — Two subsidiaries of healthcare giant Johnson & Johnson (J&J) have agreed to a $65 million settlement to resolve a long-standing class-action antitrust lawsuit. The suit, filed by various health plans and third-party payors, alleged that the companies engaged in monopolistic tactics to block generic versions of the critical pulmonary arterial hypertension (PAH) drug, Tracleer (bosentan). The settlement, filed on March 5, 2026, in the U.S. District Court for the District of Maryland, marks a significant development in the ongoing national debate over drug pricing and the strategies pharmaceutical companies use to extend market exclusivity.
The Core of the Case: Allegations of “Sample Blocking”
The litigation centered on claims that Actelion Pharmaceuticals US Inc. (acquired by J&J in 2017) and Janssen Research & Development deliberately prevented generic manufacturers from entering the market. Under the Hatch-Waxman Act, generic companies must perform bioequivalence testing to prove their version of a drug works the same way as the brand-name original. To do this, they need physical samples of the branded drug.
Plaintiffs, led by the Government Employees Health Association (GEHA), argued that J&J units refused to sell these samples to rivals and contractually barred distributors from doing so. The companies reportedly cited “safety risks” associated with the drug as the reason for restricted access. However, the lawsuit alleged this was a pretext to maintain a 100% market monopoly for nearly a decade after the original patents expired in late 2015.
By delaying competition until September 2024, the plaintiffs argued that health plans were forced to pay “supracompetitive” prices—often exceeding $70,000 annually per patient—for a therapy that should have been available at a fraction of the cost.
Understanding Tracleer and PAH
To understand the stakes of this settlement, one must understand the severity of the condition Tracleer treats. Pulmonary Arterial Hypertension (PAH) is a progressive, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. This pressure strains the right side of the heart, eventually leading to heart failure.
Tracleer (bosentan) belongs to a class of drugs called endothelin receptor antagonists. It works by blocking endothelin-1, a naturally occurring hormone that causes blood vessels to narrow. By blocking this hormone, the drug helps dilate the pulmonary arteries, improving blood flow and reducing the workload on the heart.
-
Prevalence: PAH affects an estimated 15 to 50 people per million globally.
-
Efficacy: Clinical trials demonstrated that patients taking Tracleer could walk an average of 44 meters farther in a six-minute walk test compared to those on a placebo.
-
Urgency: Without effective treatment, the median survival rate for PAH patients was historically poor, though modern therapies have extended life expectancy significantly.
Expert Perspectives on Access and Costs
Medical professionals emphasize that while Tracleer is a “lifesaving” therapy, its high cost has created significant barriers to care.
“Affordable access to endothelin antagonists is vital,” says Dr. Mardi Gomberg-Maitland, Director of the Pulmonary Hypertension Center at the University of Chicago, who was not involved in the litigation. “Monopolistic delays undermine trust in the healthcare system and, more importantly, can lead to treatment gaps for patients who may struggle with high co-pays or insurance hurdles.”
Dr. Vallerie McLaughlin, a PAH expert at the University of Michigan, has previously noted that such delays in generic entry “exacerbate access barriers for rare disease patients reliant on expensive orphan drugs.”
Settlement Details and Public Health Impact
The $65 million settlement fund is intended to compensate direct purchasers and insurers who paid for Tracleer or its generic equivalent between December 2015 and September 2024. The agreement covers 31 states, the District of Columbia, and Puerto Rico. While the J&J subsidiaries deny any wrongdoing, the settlement allows them to avoid the uncertainty and expense of a protracted trial.
The broader implications for public health are substantial. According to the Federal Trade Commission (FTC), generic competition can lower drug prices by 80% to 90%. In a healthcare system where PAH patients often require “triple therapy” (a combination of three different expensive medications), the arrival of generic bosentan is a major financial relief.
Key Statistics:
-
Estimated U.S. PAH Population: 30,000 to 40,000 patients.
-
Generic Savings: The U.S. healthcare system saved an estimated $219 billion between 2009 and 2018 due to generic drug availability.
-
Legal Fees: Plaintiffs’ attorneys are expected to seek approximately 33% ($21 million) of the settlement for legal costs.
Limitations and Counterarguments
Despite the settlement, some critics argue that $65 million is a “drop in the bucket” compared to the billions in revenue Tracleer generated during the disputed period. Furthermore, because the settlement focuses on “third-party payors” (insurers), individual patients may not see direct refunds, though they may benefit from lower future premiums or lower out-of-pocket costs now that generics are available.
The defendants maintained throughout the case that their distribution restrictions were necessary for safety. Tracleer carries “black-box warnings” for:
-
Liver Toxicity: Potential for significant hepatic impairment.
-
Birth Defects: High risk of fetal harm if taken during pregnancy.
-
Pulmonary Edema: Risk of fluid in the lungs in certain patients.
Because of these risks, the drug is managed under a Risk Evaluation and Mitigation Strategy (REMS) program. J&J argued that controlling samples was part of this safety mandate, a defense often used in “refusal to deal” antitrust cases.
The Road Ahead
The settlement now awaits final approval from the U.S. District Court. For the medical community, the case serves as a reminder of the delicate balance between rewarding pharmaceutical innovation and ensuring the competitive market remains functional.
As generic bosentan becomes more widely distributed, the focus for PAH advocates shifts toward improving early diagnosis and addressing disparities in care, ensuring that the benefits of lower costs reach the underserved populations most affected by this rare disease.
Reference Section
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
